Mode
Text Size
Log in / Sign up

Epinephrine and norepinephrine show no significant difference from dopamine in neonatal septic shockTrial shows no difference between dopamine and other drugs for infants

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that epinephrine and norepinephrine do not differ significantly from dopamine for mortality in neonatal septic shock.

This meta-analysis evaluates the comparative efficacy of epinephrine and norepinephrine versus dopamine in neonates under 28 days old experiencing fluid-refractory septic shock. The study focuses on primary outcomes of early shock reversal and all-cause mortality, alongside secondary outcomes including the need for additional vasoactive agents and changes in hemodynamic responses.

For the primary outcomes, the analysis found no significant difference between the groups. Shock reversal within 1 hour showed an RR of 1.07 (95% CI 0.84-1.36; P = 0.57) compared to dopamine. All-cause mortality also showed no significant difference (RR = 0.95; 95% CI 0.80-1.13; P = 0.58). Subgroup analyses for norepinephrine (RR = 0.97; 95% CI 0.66-1.44; P = 0.90) and epinephrine (RR = 1.16; 95% CI 0.86-1.56; P = 0.32) also showed no significant differences in shock reversal.

Secondary outcomes, including the requirement for additional vasoactive agents and mean arterial pressure, were not reported as different. The authors note that the evidence is limited by a small number of trials and considerable clinical heterogeneity. Consequently, these results should not be construed as definitive equivalence between the treatments.

How this fits prior evidence

This meta-analysis addresses the management of neonates in septic shock, a condition where malignancy has been linked to higher mortality with pooled odds ratios up to 2.41. While prior evidence suggests that early vasopressor therapy and restricted fluids do not change survival outcomes, this study specifically compares the choice of vasopressor agents (epinephrine, norepinephrine, and dopamine) in the neonatal population. It does not provide new information regarding the impact of H3.1 nucleosome levels or the role of POCUS in source identification.

When a newborn baby enters septic shock, every second counts. Doctors must act fast to stabilize the baby's blood pressure and keep their organs functioning. Because these situations are so critical, choosing the right medication is a high-stakes decision for medical teams.

Researchers looked at how different medications perform when treating these tiny patients. They compared dopamine against two other common options: epinephrine and norepinephrine. The results showed that neither epinephrine nor norepinephrine performed better than dopamine at reversing shock within the first hour. They also did not show a difference in overall survival rates for the infants.

While the data suggests these medications perform similarly, the findings come with a note of caution. The researchers noted that the small number of available trials and differences between those studies mean these results are not a definitive proof that the drugs are equal. Doctors should still weigh these options carefully based on each individual case.

What this means for you:
Epinephrine and norepinephrine showed no significant difference from dopamine in treating severe shock in newborns.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
INTRODUCTION: Neonates with fluid-refractory septic shock require prompt vasopressor support, including dopamine, epinephrine, and norepinephrine; however, the optimal first-line treatment remains unclear. This meta-analysis assessed the first-line vasopressors for shock reversal and clinical outcomes. METHODS: A comprehensive search of the PubMed, Scopus, Ovid, and CINAHL databases was performed from inception to April 2026. We included randomized controlled trials evaluating first-line vasopressor therapy in neonates (<28 days old) with fluid-refractory septic shock, comparing epinephrine and norepinephrine with dopamine. The primary outcomes were early shock reversal and all-cause mortality, with secondary outcomes including the need for additional vasoactive agents and changes in hemodynamic responses. Analyses were performed using Review Manager (RevMan) version 5.4 software. RESULTS: Four RCTs were included. Compared with dopamine, epinephrine or norepinephrine showed no significant difference in shock reversal within 1h (RR = 1.07; 95% CI = 0.84-1.36; P = 0.57; I = 39%) or mortality (RR = 0.95; 95% CI = 0.80-1.13; P = 0.58; I = 0%). Subgroup analyses showed no significant differences for norepinephrine (RR = 0.97; 95% CI = 0.66-1.44; P = 0.90; I = 73%) or epinephrine (RR = 1.16; 95% CI = 0.86-1.56; P = 0.32; I = 0%), with no difference between subgroups (P = 0.48). Secondary outcomes including the requirement of additional vasoactive agent, mean arterial pressure were not different. CONCLUSION: No substantial changes were observed in the vasoactive therapies used in neonates with fluid-refractory septic shock. Nonetheless, owing to the limited number of trials and considerable clinical heterogeneity within the studies, these results should not be construed as definitive equivalency between treatments. Additional high-quality neonatal-specific research with standardized criteria is essential to determine the most appropriate first-line treatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.